Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 534-543

  Hirai, Hiroshi ^a   Takahashi Suziki, Ikuko ^a   Shimomura, Toshiyasu ^a   Fukasawa, Kazuhiro ^a   Machida, Takumitsu ^a   Takaki, Toru ^a   Kobayashi, Makiko ^a   Eguchi, Tomohiro ^a   Oki, Hiroko ^a   Arai, Tsuyoshi ^a   Ichikawa, Koji ^a   Hasako, Shinichi ^a   Kodera, Tsutomu ^a   Kawanishi, Nobuhiko ^a   Nakatsuru, Yoko ^a   Kotani, Hidehito ^a   Iwasawa, Yoshikazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti tumor efficacy; Cdk; Pan Cdk inhibitor; Small molecule inhibitor

Indexed keywords

CASPASE 3; COMPOUND M; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; LIPOCORTIN 5; QUINOXALINE DERIVATIVE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; COLON CANCER; CONTROLLED STUDY; CRYPT CELL; DNA REPLICATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HCT116 CELLS; HUMANS; LEUKOCYTE COUNT; MACROCYCLIC COMPOUNDS; QUINOXALINES; RATS; RATS, NUDE; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953782257     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9384-8     Document Type: Article

References (28)

1. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677
2. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revised. Cancer Res 60:3689-3695
3. Pines J (1995) Cyclins ands cyclin-dependent kinases: theme and variations. Adv Cancer Res 66:181-212
4. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512 (Pubitemid 29297917)
5. Pavletich NP (1999) Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J Mol Biol 287:821-828
6. Koepp DM, Haper JW, Elledge SJ (1999) How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97:431-434 (Pubitemid 29231166)
7. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv Cancer Res 68:67-108 (Pubitemid 26099813)
8. Knockaert M, Greengard P, Meijer L (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23:417-425 (Pubitemid 35247771)
9. Falco GD, Giordan A (1998) CDK9 (PITALRE): a multifunctional cdc2-related kinase. J Cell Physiol 177:501-506
10. Price DH (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629-2634
11. Kobor MS, Greenblatt J (2002) Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta 1577:261-275 (Pubitemid 35223218)
12. Dhavan R, Tsai L-H (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749-759 (Pubitemid 33679837)
13. Lilja L, Yang S, Webb D, Juntti-Berggren L, Berggren P, Bark C (2001) Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276:34199-34205
14. Hirai H, Kawanishi N, Iwasawa Y (2009) Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Front Med Chem 4:347-370
15. Dickson MA, Schwartz GK (2009) Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16:36-43
16. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldiwney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404 (Pubitemid 46105932)
17. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT (2009) Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637-2645
18. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA (2004) Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22:315-322 (Pubitemid 39012571)
19. Grendys EC Jr, Blessing JA, Burger R, Hoffman J (2005) A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 98:249-253 (Pubitemid 41019113)
20. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC (2006) Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase II trial with clinical and pharmacodynamic endpoints. Haematologica 91:390-393
21. Benson C, White J, De Bono J, O'Donnell A, Raunaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37 (Pubitemid 46094635)
22. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM (2008) A phase I study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59-65
23. Kawanishi N, Sugimoto T, Shibata J, Nakamura K, Masutani K, Ikuta M, Hirai H (2006) Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg Med Chem Lett 16:5122-5126
24. Taya Y (1997) RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 22:14-17
25. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC (1999) Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98:859-869 (Pubitemid 29446902)
26. Malumbres M, Sotillo R, Santamaría D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118:493-504 (Pubitemid 39485668)
27. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P (2003) Cdk2 knockout mice are viable. Curr Biol 13:1775-1785 (Pubitemid 37274109)
28. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35:25-31 (Pubitemid 37048592)